

Docket No.: 41228-NC10009US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Matthew C. Fyfe

Application No.: 10/584,025

Confirmation No.: 6838

Filed: August 26, 2008

Art Unit: 1626

For: Heterocyclic Derivatives As GPCR Receptor
Agonists

Examiner: S. L. Shterengarts

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Foreign patent document CN 1379775-A corresponds with WO 01/12627-A1, both of which are cited on the enclosed PTO Form SB/08.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 50-0311, under Order No. 41228-NC10009US.

Dated: April 1, 2011

Respectfully submitted,

By 

Heidi A. Erlacher, J.D., Ph.D.

Registration No.: 45,409

Christopher E. Olson, J.D., Ph.D.

Registration No.: 55,510

MINTZ LEVIN COHN FERRIS GLOVSKY
AND POPEO, P.C.

One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Attorneys for Applicant